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Abstract
In recent pharmaceutical drug development, adaptive clinical trials become more
and more appealing due to ethical considerations, and the ability to accommodate un-
certainty while conducting the trial. Several methods have been proposed to optimize
a certain study design within a class of candidates, but finding an optimal hypothesis
testing strategy for a given design remains challenging, mainly due to the complex
likelihood function involved. This problem is of great interest from both patient and
sponsor perspectives, because the smallest sample size is required for the optimal
hypothesis testing method to achieve a desired level of power. To address these is-
sues, we propose a novel application of the deep neural network to construct the test
statistics and the critical value with a controlled type I error rate in a computation-
ally efficient manner. We apply the proposed method to a sample size reassessment
confirmatory adaptive study MUSEC (MUltiple Sclerosis and Extract of Cannabis),
demonstrating the proposed method outperforms the existing alternatives. Simula-
tion studies are also performed to demonstrate that our proposed method essentially
establishes the underlying uniformly most powerful (UMP) unbiased test in several
non-adaptive designs.
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1 Introduction
Randomized clinical trials (RCTs) remain the gold standard for understanding the effect of
a treatment or other intervention relative to placebo or standard of care (Diamond et al.,
2015; Wu et al., 2017; Barnhart et al., 2018). To facilitate the development process and
make it more ethical to patients, adaptive designs have become more and more appealing
in the past several decades, as they allow for prospectively planned modifications to design
aspects based on accumulated unblinded data (Bauer et al., 2016). For instance, the sample
size reassessment adaptive approach is to prospectively plan adjustments to the sample size
based on interim results (FDA, 2018). It has been the main focus of the adaptive design
methodology development, and remains the most frequently proposed adaptive design to
regulatory agencies for both Food and Drug Administration (FDA) (Lin et al., 2016) and
European Medicines Agency (EMA) (Elsa¨ßer et al., 2014).
A major challenge for such adaptive designs to be applied in confirmatory (Phase III)
clinical studies is the justification of type I error rate control, which is required by regula-
tory agencies (FDA, 2018; EMA, 2007). By repeatedly looking at data with the possibility
for interim sample size adjustment, one may inflate the type I error rate with usual test
statistics (Bretz et al., 2009). There are many statistical methods proposed to maintain
the trial integrity, for example by using weighted statistics (Cui et al., 1999; Lehmacher
and Wassmer, 1999) or the combination test principle (Bauer and Kohne, 1994; Liu et al.,
2002) from a frequentist perspective, and Bayesian methods (Inoue et al., 2002; Ciarleglio
et al., 2015; Ciarleglio and Arendt, 2017, 2019) to accommodate randomness in observed
data. The type I error control can be justified by either analytic derivation or proper
simulation studies. Nevertheless, identifying the uniformly most powerful (UMP) unbiased
tests (Lehmann and Romano, 2006) is also of great interest to both patients and sponsors,
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because the smallest sample size is required to achieve a desired level of power in a given
study design. A safe and efficacious drug can be delivered more efficiently to meet unful-
filled medical needs. However, it remains challenging to derive the UMP unbiased tests in
adaptive designs, due to the complex likelihood function introduced by interim adjustment
rules.
In recent years, the Deep Neural Networks (DNN) approach has made remarkable
progress and success in various domains, especially in image recognition and natural lan-
guage processing (Vogelstein et al., 2007; Perry et al., 2019; Schulz et al., 2019). It not
only provides a powerful functional representation of the complex patterns in data, but
also completely automates the step of feature engineering in previous machine-learning
techniques (Chollet and Allaire, 2018).
In this article, we propose a novel hypothesis testing framework by constructing the
test statistics from DNN to approximate the UMP unbiased test in a finite sample size.
DNN essentially learns the underlying probability of observed data being drawn from the
alternative hypothesis as compared to the null hypothesis. A proper cutoff or critical value
could be computed by simulations from null data to control the type I error rate at a
nominal level α. To avoid the time-consuming Monte Carlo method for each observed data
and to make the decision rule pre-specified, we further build another DNN to model the
critical value. A similar strategy was adopted by Chen and Zhang (2009), where the mul-
tivariate adaptive splines for analysis of longitudinal data (MASAL) (Zhang, 1997, 1999)
was utilized to estimate the empirical critical value and the number of genotyped markers
in genomewide association (GWA) studies. We apply our method to a Phase III adaptive
clinical trial MUSEC (MUltiple Sclerosis and Extract of Cannabis) with sample size re-
assessment (Zajicek et al., 2012), demonstrating the proposed method has a significantly
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higher power than the existing alternatives, and hence a smaller sample size is required.
Simulations are also performed to show that our proposed two-fold DNN guided test can
well approximate a UMP unbiased level α test in several cases of either simple or composite
hypothesis testing with either known or unknown nuisance parameters.
The remainder of this article is organized as follows. In Section 2, we introduce our
DNN-guided hypothesis testing framework in the context of non-adaptive designs with a
simple hypothesis, and provide a short review on Deep Neural Networks (DNN). We further
generalize the framework to composite hypothesis testing and adaptive designs at Section
3.2. Our method is applied to a sample size reassessment adaptive design MUSEC at
Section 4. In Section 5, we further perform simulation studies to compare our method and
known UMP unbiased tests under some cases. Concluding remarks are provided in Section
6.
2 Simple hypothesis testing
We start with a simple hypothesis testing problem of the mean µ in a Normal distribu-
tion N (µ, σ2) with the standard deviation σ as a nuisance parameter. The null hypothesis
H0 : µ = µ0 is tested against the alternative hypothesis H1 : µ = µ1 with type I error
rate controlled at a nominal level α, for example 0.05. Denote by f(x;µk, σk) the proba-
bility density functions corresponding to µk and σk with a sample x = (x1, . . . , xn) from
N (µk, σ2k), for k = 0, 1.
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2.1 Known nuisance parameter
Further assume that the nuisance parameter σ is known at value σ˜. We define a test
function φ(x) taking the value of 1 if the null hypothesis is rejected, and 0 otherwise. The
rejection region is given by R(φ) = {x : φ(x) = 1}. Based on the Neyman-Pearson Lemma,
a test φ(x) that satisfies
φ(x) = I [f(x;µ1, σ˜) > kf(x;µ0, σ˜)] , (1)
α = PrH0 [x ∈ R(φ)] ,
for some k ≥ 0, is a uniformly most powerful (UMP) level α test, and is also a UMP
unbiased level α test (Lehmann and Romano, 2006). To explicitly derive this test, one first
expresses the rejection region R in (1) as µ̂(x) > c, where µ̂(x) =
∑n
j=1 xj/n is a sufficient
statistic for µ. The constant c = σ˜z1−α/
√
n + µ0 is chosen such that PrH0 [µ̂(x) > c] = α,
where zu = Φ
−1(u). In this simple setup, the z-test is a UMP level α test. However,
when the likelihood function is complicated, it is usually hard to derive the distribution
of the sufficient statistics in a finite sample, as with the case study of adaptive design we
considered at Section 4.
As an alternative, we formulate the hypothesis testing in the context of a binary classi-
fication problem to categorize whether x is sampled from the alternative hypothesis H1 or
from the null hypothesis H0. We introduce a latent indicator y ∈ {0, 1} indicating where
x is sampled. Given y = k, the conditional probability density function or the probability
mass function is equal to f(x;µk, σ˜), for k = 0, 1. Therefore, the rejection region in (1)
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can be expressed as
f(x;µ1, σ˜) > kf(x;µ0, σ˜) ⇐⇒ f(x;µ1, σ˜)Pr(y = 1)
f(x;µ0, σ˜)Pr(y = 0)
> k′
⇐⇒ Pr(y = 1|x, σ˜)
1− Pr(y = 1|x, σ˜) > k
′
⇐⇒ d (x; σ˜) > log(k′) ≡ d′, (2)
where d (x;σ) = sigmoid−1 [Pr(y = 1|x, σ)] and sigmoid(u) = 1/ (1 + e−u). A larger value
of d (x; σ˜) indicates that x is more likely to be drawn from H1 as compared to H0. The
constant d′ in (2) is set at d(c)(α) such that
PrH0
[
d (x; σ˜) > d(c)(α)
]
= α, (3)
to control the type I error rate at α. Based on the sufficiency part of the Neyman-Pearson
Lemma, any test that satisfies (2) and (3) is a UMP level α test. The question then becomes
how to model d (x; σ˜) in (2).
Next we provide a short review of DNN which defines a mapping y = q(t;ψ) and learns
the value of the parameters ψ that result in the best function approximation of output
label y based on input data t (Goodfellow et al., 2016). The deep in DNN stands for
successive layers of representations. For example, in a DNN with two layers denoted as
q(t;ψ(1),ψ(2)) = q(2)
(
q(1)
(
t;ψ(1)
)
;ψ(2)
)
, the data t and parameters ψ(1) are transformed
by activation function q(1) in the first layer, and then transformed by q(2) in the second layer
to approximate y. The last-layer activation function is commonly chosen as the sigmoid
function for binary classification and the linear function for a continuous variable approxi-
mation (Chollet and Allaire, 2018), while the inner-layer activation function is usually the
ReLU function defined by ReLU(u) = max(0, u) (Jarrett et al., 2009).
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In our proposed hypothesis testing framework, we utilize a DNN to characterize the
functional form of d (x; σ˜) or equivalently the likelihood ratio f(x;µ1, σ˜)/f(x;µ0, σ˜) in (2),
and further determine a rejection region with a controlled type I error at α in (3). For
a sample with index b, we define an auxiliary random variable yb taking value either 0
or 1, where the event {yb = k} indicates a sample xb being drawn from the distribution
under Hk, for k = 0, 1. In the Step 1 of Algorithm 1, we generate B0 training data with
yb = 0 and B1 data with yb = 1 for the binary classification problem. We further utilize
d(s)
[
µ̂(x);ψ
(s)
0 , σ˜
]
constructed by DNN to approximate d (x; σ˜) satisfying∣∣∣∣∣d(s) [µ̂(x);ψ(s)0 , σ˜]− d (x; σ˜)
∣∣∣∣∣ < , (4)
where µ̂(x) is a sufficient statistics of µ, ψ
(s)
0 is the parameter in DNN,  ( > 0) is a small
error term, and σ˜ is the known value of the nuisance parameter σ. For example, in a DNN
with two layers, one has d(s)
[
µ̂(x);ψ
(s)
0 , σ˜
]
= q(1)
(
µ̂(x);ψ
(s)
0
)
and q(2)(·) = sigmoid(·). By
the Fisher-Neyman factorization theorem of a sufficient statistic, we also have d (x; σ˜) =
d [µ̂(x); σ˜]. Based on the universal approximation theorem and its extensions,  in (4)
can be arbitrarily small by using a depth-2 DNN with a sufficiently larger number of
nodes if d [µ̂(x); σ˜] is continuous (Cybenko, 1989), or by using a sufficiently flexible DNN
if d [µ̂(x); σ˜] is Lebesgue integrable (Lu et al., 2017).
However, the relatively larger number of parameters in ψ
(s)
0 can easily make DNN overfit
the training data and lose generalized ability to the new data. In Step 2, a proper DNN
structure is selected from several candidates by cross-validation with 80% as the training
data and the remaining 20% as the validation data (Goodfellow et al., 2016). In choosing
the candidate pool of DNN structures, one usually starts with a simple skeleton with small
numbers of nodes and layers. By making DNN wider and deeper, typically the validation
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error first gets smaller and then peaks up. One can further propose several structures
around this suboptimal solution in the candidate pool. The final optimal structure is the
one with the smallest validation error. From Section 4 and 5, the performance of our
method is consistent across different DNN structures given that their validation error is
relatively small.
In Step 3, DNN seeks a solution ψ̂
(s)
which maximizes the log likelihood function,
ψ̂
(s)
= arg max
ψ
B0+B1∑
b=1
{
(1− yb) log
(
1− p(s) [µ̂(xb);ψ, σ˜]
)
+ yb log p
(s) [µ̂(xb);ψ, σ˜]
}
, (5)
where p(s) [µ̂(x);ψ, σ] = sigmoid
(
d(s) [µ̂(x);ψ, σ]
)
. Essentially, DNN obtains ψ̂
(s)
as the
Maximum Likelihood Estimate (MLE) of ψ
(s)
0 in (4), and hence d
(s)
[
µ̂(x); ψ̂
(s)
, σ˜
]
approx-
imates the underlying d (x; σ˜) in (2). In Step 3, d(c)(α) in (3) is evaluated empirically
based on a set of validation data {xb′}B′b′=1 simulated from H0. We reject H0 at level α if
d(s)
[
µ̂(x); ψ̂
(s)
, σ˜
]
> d(c)(α).
2.2 Unknown nuisance parameters
If the nuisance parameter σ is unknown, then we substitute it in (2) by its MLE σ̂(x) =[∑n
j=1(xj − x¯)2/n
]1/2
to obtain d(x; σ̂). We propose to build a more general DNN with
varying σ’s to characterize the underlying d(x;σ), and utilize a second-fold DNN to estimate
the critical value. In the Step 1 of Algorithm 2, a total number of A training datasets are
aggregated, where each subset has a fixed standard deviation at σa, for a = 1, · · · , A, as
in the Algorithm 1. The range of {σa}Aa=1 should be wide enough to cover the potential
minimum and maximum of σ̂(x) from observed data x. For example, in the simulation
study of Section 5.2, {σa}Aa=1 contains 0.6 as a lower bound if x has a sample size of
100 with standard deviation 1. The same range of {σa}Aa=1 is applied to the range of
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Algorithm 1 A DNN-guided UMP level α test with known nuisance paramters
Step 1: Build training data for DNN
Simulate B0 samples from the null hypothesis H0 and B1 samples from the alternative
hypothesis H1. The input is µ̂(xb) as a sufficient statistics for µ, and the classification
label yb is 1 if the sample is simulated from H1 while 0 otherwise, for b = 1, · · · , B0 +B1.
Step 2: Utilize cross-validation to select the structure of DNN
Details of the cross-validation are provided in Section 2.1.
Step 3: Train a selected DNN to obtain d(s)
[
µ̂(x); ψ̂
(s)
, σ˜
]
Train a DNN with the ReLU as the inner-layer activation function and the sigmoid as
the last-layer activation function. The linear predictor is denoted as d(s)
[
µ̂(x); ψ̂
(s)
, σ˜
]
.
Step 4: Compute the cutoff value d(c)(α) in the decision rule
Simulate a set of validation data from H0 with size B
′, and denote their linear predictors
as
{
d(s)
[
µ̂(xb′); ψ̂
(s)
, σ˜
]}B′
b′=1
. Set the cutoff value d(c)(α) in (3) as the upper α quantile.
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{σl}Ll=1 as the training data of the second-fold DNN to model the critical value at Step
3. Having observed a new data x˜, we plug t˜
(s)
= [µ̂(x˜), σ̂(x˜)] into d(s)
[
t˜
(s)
; ψ̂
(s)
]
to
compute the test statistics, and σ˜(x˜) into d(c)
[
σ˜(x˜); ψ̂
(c)
, α
]
for the critical value, where
σ˜(x˜) =
[∑n
j=1(xj − x¯)2/(n− 1)
]1/2
as an unbiased estimator of σ.
The proposed two-fold DNN guided hypothesis testing framework not only makes the
decision rule pre-specified, but is also computationally efficient as compared to re-sampling
based approaches, such as the parametric bootstrap method (Efron and Tibshirani, 1994).
One does not need to simulate a relatively large number of null datasets for each observed
data x˜.
A similar automatic procedure was adopted in Chen and Zhang (2009), where they uti-
lized multivariate adaptive splines for analysis of longitudinal data (MASAL) (Zhang, 1997,
1999) to model the empirical critical value from the generalized extreme value distribution
(GEV) and the number of genotyped markers in genomewide association (GWA) studies.
MASAL finds a simple while accurate piecewise linear approximation to the underlying
smooth curve and estimates correlations between observations by EM-type iterative proce-
dure. In practice, the convergence of covariance structure estimation needs to be examined
by results from several iterations (Zhang, 2004). On the other hand, our second-fold DNN
does not necessarily assume a smooth underlying function of critical values, and could be
generally applied to complex settings, for example the adaptive design in the next section.
3 Composite hypothesis testing
The previous section on simple hypothesis testing is mainly of theoretical interest, since the
problem arising in drug development typically involves a composite hypothesis, for example
11
Algorithm 2 A DNN-guided UMP level α test with unknown nuisance paramters
The first-fold DNN for test statistics
Step 1: Build aggregated training data for the first DNN
Stack A sets of training data from Step 1 of Algorithm 1 to construct an aggregated
training data with A × (B0 + B1) total samples. The input vector t(s)b for sample b
contains µ̂(xb) and σ̂(xb).
Step 2: Train the first DNN using the selected structure by cross-validation
to obtain the test statistic d(s)
[
t(s); ψ̂
(s)
]
Same as Step 2 and 3 in Algorithm 1.
The second-fold DNN for critical values
Step 3: Build training data for the second DNN
The training input data are σl, for l = 1, · · · , L. The training output label for each
σl is the upper α quantile in linear predictors
{
d(s)
[
t
(s)
b′ ; ψ̂
(s)
]}B′
b′=1
simulated from null
distribution f (x;µ0, σl).
Step 4: Train the second DNN using the selected structure by cross-validation
to obtain the critical value d(c)
[
σ; ψ̂
(c)
, α
]
Same as the Step 2 and 3 in Algorithm 1 but use linear function as the last-layer activation
function in DNN training with parameters estimated at ψ̂
(c)
.
Hypothesis testing for an observed data x˜
Calculate the input data t˜
(s)
= [µ̂(x˜), σ̂(x˜)] based on x˜ for the first DNN, and further
compute its corresponding test statistic d(s)
[
t˜
(s)
; ψ̂
(s)
]
. Use the second DNN to obtain
the critical value d(c)
[
σ˜(x˜); ψ̂
(c)
, α
]
, and reject H0 if d
(s)
[
t˜
(s)
; ψ̂
(s)
]
> d(c)
[
σ˜(x˜); ψ̂
(c)
, α
]
.
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testing if the efficacy of a treatment is superior to placebo. In Section 3.1, we introduce
a general framework of our proposed deep learning guided hypothesis testing method, and
apply it to adaptive designs at Section 3.2.
3.1 A general framework
Suppose that we have two samples xg of size ng, where g = t denoting the treatment group
and g = p for the placebo group, from a probability density function (or probability mass
function) f(xg;θg,φg), where θg is the parameter of interest and φg is for the nuisance
parameter. We consider a one-sided composite hypothesis testing of H0 : θp = θt versus
H1 : θp < θt with type I error rate controlled at α, if a larger θ corresponds to a better
clinical outcome. This is equivalent to test H1 : ∆ > 0 versus H0 : ∆ = 0, where
∆ = θt − θp.
We generalize Algorithm 2 at Section 2.2 by accommodating varying ∆’s to Algo-
rithm 3. Denote ∆̂(xp,xt) = θ̂(xt) − θ̂(xp), where θ̂(x) is the MLE of θ given data
x. Correspondingly, φ̂(x) is the MLE of φ. We define θ˜(·) and φ˜(·) as unbiased esti-
mates of θ and φ, respectively. At Step 1, the input data t(s) for the first DNN incor-
porates ∆̂(xp,xt), φ̂(xp) and φ̂(xt) to construct the test statistics. At Step 3 of train-
ing the second DNN to model the critical value, the underlying θpt,φp,φt are included
in the input t(c), where θpt are the common parameter of interest for two groups under
H0. After observing data x˜p and x˜t, one first computes the DNN constructed test statis-
tic d(s)
[
t˜
(s)
; ψ̂
(s)
]
with t˜
(s)
=
[
∆̂(x˜p, x˜t), φ̂(x˜p), φ̂(x˜t)
]
, and then calculates the critical
value t˜
(c)
=
[
θ˜(x˜pt), φ˜(x˜p), φ˜(x˜t)
]
, where x˜pt = (x˜p, x˜t). The decision is to reject H0 if
d(s)
[
t˜
(s)
; ψ̂
(s)
]
> d(c)
[
t˜
(c)
; ψ̂
(c)
, α
]
.
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Algorithm 3 A general framework of DNN guided hypothesis testing
The first-fold DNN for test statistics
Step 1: Build aggregated training data for the first DNN
Stack A sets of data with B0 samples from H0 and B1 samples from H1 to construct an
aggregated training data. The input vector t(s) contains ∆̂(xp,xt), φ̂(xp) and φ̂(xt).
Step 2: Train the first DNN using the selected structure by cross-validation
to obtain the test statistic d(s)
[
t(s); ψ̂
(s)
]
Same as Step 2 and 3 in Algorithm 1.
The second-fold DNN for critical values
Step 3: Build training data for the second DNN
The training input data are
{
t
(c)
l
}L
l=1
of size L, where t
(c)
l = (θpt,l,φp,l,φt,l). The out-
put label for each t
(c)
l is the upper α quantile in linear predictors
{
d(s)
[
t
(s)
b′ ; ψ̂
(s)
]}B′
b′=1
for data
{
t
(s)
b′
}B′
b′=1
simulated from null distribution f(xp;θpt,l,φp,l) for placebo and
f(xt;θpt,l,φt,l) for the treatment group.
Step 4: Train the second DNN using the selected structure by cross-validation
to obtain the critical value d(c)
[
t(c); ψ̂
(c)
, α
]
Same as Step 2 and 3 in Algorithm 1 but use linear function as the last-layer activation
function in DNN training with parameters estimated at ψ̂
(c)
.
Hypothesis testing for observed data x˜p and x˜t
Calculate the input data t˜
(s)
=
[
θ̂(x˜p)− θ̂(x˜t), φ̂(x˜p), φ̂(x˜t)
]
for the first DNN, and
compute its corresponding test statistic d(s)
[
t˜
(s)
; ψ̂
(s)
]
. Use the second-fold DNN to
obtain the critical value d(c)
[
t˜
(c)
; ψ̂
(c)
, α
]
, where t˜
(c)
=
[
θ˜(x˜pt), φ˜(x˜p), φ˜(x˜t)
]
. Reject
H0 if d
(s)
[
t˜
(s)
; ψ̂
(s)
]
> d(c)
[
t˜
(c)
; ψ̂
(c)
, α
]
.
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3.2 Adaptive designs with sample size reassessment
Now let us apply Algorithm 3 to a sample size adaptive clinical trial in the context of a
binary endpoint to evaluate the efficacy profile of a treatment group versus placebo with
1 : 1 randomization ratio. If a larger response rate corresponds to a better outcome, then
the null and alternative hypothesis are:
H0 : pit = pip, H1 : pit > pip, (6)
where pip and pit are the response rates in the placebo and the treatment group, respectively.
This is equivalent to testing if the response difference ∆ = pit − pip is larger than 0 or if it
is equal to 0. The number of responders xp in the control and xt in the treatment group
are assumed to follow two independent Binomial distributions.
In a non-adaptive design, there exits a UMP unbiased test of hypothesis (6) by Theorem
4.4.1 (Lehmann and Romano, 2006), because the joint distribution of xp and xt is in an
exponential family. The UMP unbiased test is in terms of the conditional distribution
of xt on xp + xt, which is the hypergeometric distribution. An approximate test whose
overall level tends to be closer to α is obtained by using the Normal approximation to the
hypergeometric distribution without continuity correction,
m(xp, xt, n) =
xt/n− xp/n√
2pi(1− pi)/n, (7)
where pi = (xt +xp)/(2n), and n is the sample size per group. More details and discussions
could be found in Section 4.5 in Lehmann and Romano (2006).
Now consider a two-stage adaptive design with a sample size reassessment at the interim
analysis. Denote by xp1 and xt1 the number of responders in the placebo and treatment
group, respectively, and by n1 the sample size per group in the first-stage. Correspondingly,
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xp2, xt2 and n2 as the notations in the second-stage. Having observed interim data (xp1, xt1),
one can adjust n2 based the following conditional power to achieve a desired pre-specified
power (Mehta and Pocock, 2000):
CP (m1, n2, pit, pip) = Φ
[
zα
√
n1 + n2 +m1
√
n1√
n2
+
(pit − pip)√n2√
2pi(1− pi)
]
,
where m1 = m(xp1, xt1, n1) as defined in (7) and pi = (pit + pip)/2. The pit, pip and pi can be
estimated by their empirical counterparts. However, uncertainty and variability of those
parameters need to be considered to protect against misspecification of the hypothesized
treatment effect (Ciarleglio and Arendt, 2017). Conditional expected power (CEP), on
the other hand, provides a robust alternative by averaging the traditional CP using prior
distribution of pit and pip, p(pit) and p(pip), respectively (Ciarleglio et al., 2015; Ciarleglio
and Arendt, 2019):
CEP (m1, n2) =
∫
pit
∫
pip
CP (m1, n2, pit, pip)p(pip)p(pit)dpipdpit. (8)
Having observed the first data for adaptation, one adjusts n2 as the minimum integer for
CEP (m1, n2) to achieve a targeted level CEPt, for example CEPt = 80%. For a practical
consideration, n2 is upper bounded by n2,max due to cost and timeline constraints, and is
lower bounded by n2,min in order to build a required safety profile.
Contrary to non-adaptive designs, it is challenging to characterize the joint distribution
of the number of responders under the null hypothesis, because the value of n2 is adjusted
based on observed accumulated data in the first-stage. By adopting Algorithm 3, we
include the MLEs of ∆ by using data from two stages separately, and n2 in the first DNN
training dataset, i.e., t(s) = (xt1/n1 − xp1/n1, xt2/n2 − xp2/n2, n2). In constructing the
second-fold DNN to model critical values, the training data t(c) includes the underlying
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null response rate pipt. For an observed data, its empirical estimator (xc1 +xt1)/(2n1) based
on the first-stage data is an unbiased estimator of pipt under H0, and hence is plugged into
d(c)
[
t˜
(c)
; ψ̂
(c)
, α
]
to compute the critical value.
4 Sample size reassessment in the MUSEC trial
In this section, we apply our proposed method to the Phase III clinical trial MUSEC
(MUltiple Sclerosis and Extract of Cannabis, Trial Registration Number NCT00552604,
Zajicek et al. (2012)), which implemented an adaptive design with sample size re-estimation
to investigate a standardized oral cannabis extract (CE) for the symptomatic relief of muscle
stiffness and pain in adult patients with stable multiple sclerosis and ongoing troublesome
muscle stiffness.
The primary outcome measure was a binary endpoint of patient reporting “relief of
muscle stiffness” from baseline to 12 weeks of treatment based on an 11-point category
rating scale. Sample size calculations were based a response rate of 0.42 in CE and 0.27
in placebo from previous studies, and therefore 170 subjects per group gives the Fisher
exact test 80% power with a two-sided type I error rate of 5% (Zajicek et al., 2012). An
unblinded interim analysis was planned when 50% of the total subjects had developed
their 12-week outcomes. The Independent Data Monitoring Committee (IDMC) made
the recommendation to reduce the total number of subjects to be enrolled by 100 as the
adjusted sample size was sufficient to maintain a conditional power of 95%.
To evaluate the performance of our proposed method, we re-design this adaptive design
by treating the primary endpoint as an instant binary response whose observation is avail-
able right after patient’s enrollment. The one-sided type I error rate is to be controlled
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at the nominal level 0.05, and the response rate in the treatment group is considered at
0.4 for illustration. With an interim analysis at 50% information rate, the sample size per
group in the first-stage is n1 = 85. We consider the sample size reassessment framework
based on the conditional expected power (CEP) in Section 3.2. Beta distributions with
mean at observed rates and the same variance γ are assumed as the prior for pic and pit
(Ciarleglio and Arendt, 2017). The CEP in (8) is evaluated by Monte Carlo integration
with 10, 000 iterations. The second-stage sample size per group n2 is adjusted for CEP
to reach CEPt = 80%. The lower limit is set at n2,min = 21 while the upper bound is at
n2,max = 340.
In Algorithm 3 of our proposed method, we aggregate A = 46 datasets for pic scanning
from 0.05 to 0.5 with an increment of 0.01 and B0 = B1 = 5× 105. The corresponding pit
is computed for the proportional test in (7) to achieve 85% power, and hence the resulting
pic = 0.27 and pit = 0.4 are aligned with the response assumptions. In the validation step, we
also considered scenarios where the observed pit is lower or higher than the assumption. The
DNN structure is selected as the one with the smallest validation error in cross-validation
from 4 candidates, which are all combinations of the number of layers at 2 and 4, and the
number of nodes per layer at 10 and 40. The number of epochs is 10, the batch size is 104,
and the dropout rate is set at 0.1. The same structure candidate pool is applied to the rest
of this article for the first-fold DNN to construct the test statistic.
In Step 3 of modeling the second DNN, we simulate L = 100 training data with varying
null response rate pipt as a regular sequence from 0.05 to 0.5. The moderate size L = 100 is
sufficient to give us a validation mean squared error loss approximately 10−3 in the second
DNN, and to deliver an accurate type I error rate control as can be seen later on. The
structure candidate pool for the second DNN includes all combinations of the number of
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layers at 2 and 3, and the number of nodes per layer at 30, 40 and 50. The dropout rate
is set at 0.1, the batch size is 10, and the number of epochs is 103. The critical value is
computed based on B′ = 106 samples. We further simulate another 106 validation data
to evaluate the type I error rate control and power performance. The 106 iterations for
computing the critical value and for simulating validation data is used throughout this
article.
The inverse normal combination test approach (Lehmacher and Wassmer, 1999) with
equal weights, denoted as “INCTA”, and a Bayesian method with adjusted critical value
(Ciarleglio and Arendt, 2017, 2019), denoted as “BM”, are conducted for comparison. We
also compute the average sample size (ASN), which is the same for all three methods within
a scenario.
The structure of the first DNN is selected at 40 nodes per layer and 4 layers. The second
DNN has 40 nodes and 2 layers. We first consider a study design with CEPt = 80% for
the target CEP and γ = 0.001 for the prior beta distribution variance. The type I error
is studied under null response rate at 0.17, 0.22, 0.27, 0.32 and 0.37, which establish a
reasonable range around the observed control rate at 0.27. As shown in Table 1, both our
proposed method and INCTA have an accurate controlled type I error rate at 0.05. The
critical value in the BM is adjusted to 0.033 to protect the type I error across all evaluated
response rates. In the Supplemental Materials Table 1, we further evaluate the type I error
protection in cases where the sampling distribution is a mixture of 90% assumed binary
distribution and a 10% uniform distribution with minimum at 0, and maximum at twice
the response rate. Our method has a more conservative type I error rate as compared with
the two alternatives, and hence is more robust to model misspecifications.
Under the training alternative hypothesis pip = 0.27 and pit = 0.4, our method has the
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highest power at 94.5% as compared with 88.7% from INCTA and 91.7% from BM (Table 1).
By performing 20 replicates of the validation process, we find that all three methods have a
relatively small standard deviation at approximately 0.03%, demonstrating the robustness
of our findings. The power performance of DNN method remains the highest when the
observed response rate is higher or lower than the assumed pit = 0.4. By adjusting the
magnitude of n2,max, we compute the average sample size (ASN) for each design to achieve
90% power at Table 2. In the case where pip = 0.27 and pit = 0.4, our method has the
smallest sample size per group requirement at 189, which corresponds to a 30.5% saving
relative to INCTA with 272, and a 6.9% saving against BM with 203. In the corresponding
heatmap at Figure 1, we plot the conditional probability of rejecting H0 given the number
of responders in CE and Placebo group. All three methods have similar decision zone of
favoring H1 if CE has more observed responders than the Placebo.
Three other designs with varying CEPt’s and γ’s are evaluated at Table 3, demon-
strating a consistent power gain of our proposed method, along with an accurate type I
error control. In the Supplemental Materials Table 2, we show that the performance of our
proposed method is robust with different DNN structures.
5 Simulation studies
In this section, we evaluate the performance of our DNN guided hypothesis testing frame-
work under three setups: simple hypothesis testing with known nuisance parameters at
Section 5.1, simple hypothesis testing with unknown nuisance parameters at Section 5.2,
and composite hypothesis testing at Section 5.3. We essentially show that our method
learns the existing UMP unbiased tests in simple hypothesis testing settings, and performs
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pip ∆ Type I error / Power ASN
DNN INCTA BM
0.17 0.00 5.0% 5.0% 5.0% 405
0.22 0.00 5.0% 5.1% 5.0% 404
0.27 0.00 5.0% 5.0% 5.0% 403
0.32 0.00 5.1% 5.1% 5.0% 402
0.37 0.00 5.1% 5.0% 5.0% 403
0.27 0.12 90.9% 85.9% 88.8% 250
0.27 0.13 94.5% 88.7% 91.7% 227
0.27 0.14 96.7% 90.7% 93.7% 208
Table 1: Type I error rate and power in sample size reassessment design with CEPt = 80%
and γ = 0.001
no worse than a popular approximate method in a composite hypothesis testing case.
5.1 Simple hypothesis testing for mean of a Normal distribution
with known standard deviation
Consider the setup in Section 2.1, where the mean µ of a Normal distribution with known
standard deviation σ˜ is tested at level α = 0.05 for hypothesis H1 : µ = µ1 versus H0 :
µ = µ0. In this simple hypothesis testing problem, the z-test is a UMP level α test. We
consider µ0 = 0, and choose µ1 as the alternative mean for the z-test to achieve a 50% or
90% power. In Algorithm 1, the training dataset size B0 and B1 are set to be 5 × 105 at
Step 1.
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pip ∆ ASN
DNN INCTA BM
0.27 0.12 242 389 284
0.27 0.13 189 272 203
0.27 0.14 152 198 158
Table 2: Average sample size (ASN) to achieve 90% power in sample size reassessment
design with CEPt = 80% and γ = 0.001
By cross-validation, the DNN structure with four layers, and ten nodes per layer has
the smallest validation error, and is utilized for the final model fitting. As can be seen
from Table 4, our proposed method accurately controls the type I error rate at the nominal
level 0.05 across all scenarios with varying n’s and σ˜’s. It also consistently reaches the
upper power limit as the power of the z-test. We further conduct a sensitivity analysis of
the hyperparameters in DNN under n = 100 and σ˜ = 1.5. Results at the Supplemental
Materials Table 3 demonstrate that the performance of our proposed method is robust with
the training data size B0 and B1 from H0 and H1, the number of nodes, layers and the
dropout rate in DNN.
5.2 Simple hypothesis testing for mean of a Normal distribution
with unknown standard deviation
Next we consider a scenario with an unknown standard deviation, where the one-sample
t-test is a UMP level α test. The sample size n is considered at 100 and 200. We set
µ0 = 0 and choose the value of µ1 for the one-sample t-test to reach approximately 90%
power. In Step 1 of Algorithm 2, we aggregate A = 10 training dataset with {σa}Aa=1 =
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{0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4} and B0 = B1 = 105. We generate L = 102 regular
sequences from 0.6 to 2.4 as the input data {σl}Ll=1 in training the second-fold DNN for
modeling the critical value. In the validation step, we consider cases with σ0 = 1 and 2,
which are included in the set {σa}Aa=1, but σ0 = 1.5 is not.
The structure of the first DNN is selected at ten nodes per layer and four layers. The
second DNN has forty nodes and two layers. As shown Table 5.2, our DNN based method
reaches the upper power limit from the one-sample t-test with a controlled type I error rate
at 0.05 across all scenarios evaluated.
5.3 Composite hypothesis testing for mean of two Normal dis-
tributions with unknown standard deviation
In this section, we consider the so-called Behrens-Fisher problem of testing the equality of
the means µp and µt from two Normal distributions with unknown standard deviations σp,
σt and no equal variance assumption (Behrens, 1929; Fisher, 1935). The H1 : ∆ > 0 is
tested against the H0 : ∆ = 0 at level α = 0.05, where ∆ = µt − µp. Deriving the UMP
unbiased test is challenging, because the sufficient statistics are not complete (Lehmann
and Romano, 2006). The Welch approximate t-test is a popular approximate solution that
are satisfactory for practical purposes (Welch, 1951).
In constructing our DNN guided hypothesis testing strategy by Algorithm 3, we aggre-
gate A = 50 sets of data to include all combinations of σp and σt in (0.8, 0.9, 1, 1.1, 1.2),
and µt taking values for the Welch’s t-test to achieve approximately 60% and 80% power
at level α = 0.05 at Step 1. Other parameters are set as: µp = 0, B0 = B1 = 5 × 105 and
n = 100 per group. At step 3 of training the second DNN, we generate a size L = 100
of null data with the common mean value µpt = 0, σp and σt taking values in 10 regular
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sequences from 0.8 to 1.2. Since the Normal distribution is in a location-scale family, then
the critical value is invariant under varying µpt. Therefore, it is sufficient to fix µpt at Step
3, and to exclude the unbiased estimator of µpt from t
(c) at Step 4. In the validation stage,
the σp and σt are evaluated at 0.95 and 1.1, and µp at 0.5. The nuisance standard deviation
0.95 is not incorporated in the previous training step, and is utilized to test the predictive
performance of our method. The µt is also considered at a lower value as compared with
the magnitude to achieve 80% power in the training step.
After conducting the cross-validation, the first DNN has 10 nodes per layer and 2 layers,
while the second DNN has 30 nodes and 2 layers. Across all scenarios in Table 5.3, our DNN
has an accurate type I error protection at 0.05, and has a consistent power performance
as compared to the Welch’s t-test. Marginal power gain of DNN method is also available
in some cases, for example 72.3% compared with 72.1% when σp = 1.1, σt = 0.7 and
µt = 0.848.
6 Discussions
In this article, we propose a novel DNN-guided hypothesis testing framework to target the
UMP unbiased test in sample size reassessment adaptive clinical trials. Our method has
moderate power gain compared to several alternatives, and has accurate type I error rate
control at a nominal level. The pre-specified decision rule not only makes the computation
more efficient, but is also more acceptable to regulatory agencies. The well-trained DNNs
can be locked in files before the conduction of the current trial to ensure the study integrity.
The proposed framework can be generally applied to other hypothesis testing problems
if the potential UMP unbiased tests are hard to derive. A future work is to generalize
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our method to multiple hypothesis testing problems, for example seamless Phase II/III
design, where familywise error rate (FWER) needs to be properly controlled under all
configurations of true and false null hypotheses.
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Figure 1: Heatmap of conditional power under the null and the alternative hypothesis for
sample size reassessment design with CEPt = 80% and γ = 0.001
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CEPt γ pip ∆ Type I error / Power
DNN INCTA BM
0.8 0.005 0.17 0.00 5.1% 5.1% 5.0%
0.22 0.00 5.1% 5.0% 5.0%
0.27 0.00 5.0% 5.1% 5.0%
0.32 0.00 5.0% 5.0% 5.0%
0.37 0.00 5.1% 5.1% 5.1%
0.27 0.12 94.8% 89.1% 93.3%
0.27 0.13 97.6% 91.3% 95.5%
0.27 0.14 98.9% 92.7% 96.3%
0.75 0.001 0.17 0.00 4.9% 5.1% 5.2%
0.22 0.00 4.9% 5.0% 5.0%
0.27 0.00 5.1% 5.1% 5.2%
0.32 0.00 5.0% 5.0% 5.0%
0.37 0.00 5.1% 5.1% 5.2%
0.27 0.12 88.9% 84.4% 87.1%
0.27 0.13 93.0% 87.2% 90.0%
0.27 0.14 95.3% 89.3% 92.2%
0.75 0.005 0.17 0.00 5.1% 5.1% 5.1%
0.22 0.00 5.0% 5.1% 5.1%
0.27 0.00 5.0% 5.0% 5.0%
0.32 0.00 5.1% 5.1% 5.1%
0.37 0.00 5.1% 5.0% 5.1%
0.27 0.12 92.9% 87.2% 90.8%
0.27 0.13 96.2% 89.7% 93.4%
0.27 0.14 97.9% 91.2% 94.9%
Table 3: Sample size reassessment designs with varying CEPt’s and varying γ’s
31
n σ˜ µ0 µ1 Type I error Power
DNN z-test DNN z-test
50 1 0 0.233 5.0% 5.0% 50.0% 50.0%
0.414 5.0% 5.0% 90.0% 89.9%
150 2 0.269 5.0% 5.0% 50.0% 50.0%
0.478 5.0% 5.0% 90.1% 90.0%
Table 4: Type I error rate and power in simple hypothesis testing with known standard
deviation
n σ˜ µ0 µ1 Type I error Power
DNN One-sample t-test DNN One-sample t-test
100 1.0 0 0.293 5.0% 5.0% 89.7% 89.6%
1.5 0.439 5.0% 5.0% 89.7% 89.7%
2.0 0.585 4.9% 5.0% 89.5% 89.6%
200 1.0 0.207 5.0% 5.0% 89.8% 89.8%
1.5 0.310 5.0% 5.0% 89.8% 89.8%
2.0 0.414 5.0% 5.0% 89.7% 89.8%
Table 5: Type I error rate and power in simple hypothesis testing with unknown standard
deviation
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σp σt µp µt Type I error Power
DNN Welch’s t-test DNN Welch’s t-test
0.95 0.95 0.5 0.834 5.0% 5.0% 79.7% 79.7%
0.801 - - 72.0% 72.0%
1.1 0.7 0.861 5.0% 5.0% 79.8% 79.7%
0.825 - - 72.2% 72.2%
1.1 0.95 0.5 0.861 5.0% 5.0% 79.8% 79.8%
0.825 - - 72.1% 72.0%
1.1 0.7 0.887 5.0% 5.0% 79.9% 79.8%
0.848 - - 72.3% 72.1%
Table 6: Type I error rate and power in composite hypothesis testing with unknown stan-
dard deviation
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